Clinical trials
Bone Cancer Metastatic clinical trials
Below are recruiting bone cancer metastatic clinical trials, each written for real people, not researchers. We’re tracking 738 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06222879RecruitingPhase 1/Phase 2
New drug combinations for advanced breast cancer
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
Changsha, HunanAges 18–75 - NCT06711471RecruitingPhase 2
Combination therapy for advanced stomach cancer after prior treatments
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07461454RecruitingPhase 3
Comparing YL202 to other treatments for HR+/HER2- breast cancer
This trial tests a new drug called YL202 against other treatments chosen by your doctor for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to see if YL202 works better. You may join if your cancer has spread, you've already tried chemotherapy, and you meet other health criteria.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07392346RecruitingPhase 2
Fruquintinib combo for advanced gastric cancer after immunotherapy
This trial tests a combination of targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and two immunotherapies (iparomlimab and tuvonralimab) for people with advanced stomach or gastroesophageal junction cancer whose first treatment with a PD-1/PD-L1 inhibitor stopped working. The goal is to see if this new combination can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03579836RecruitingPhase 1/Phase 2
Test BEY1107 plus gemcitabine for pancreatic cancer
This early study tests whether BEY1107 given alone or with gemcitabine can be used safely and may help shrink pancreatic cancer tumors. It mainly looks at safety, side effects, and signs of effectiveness in people with pancreatic ductal cancer.
SeoulAges 20–80 - NCT07207070RecruitingPhase 3
New drug combination for PIK3CA-mutated breast cancer
This trial tests a new combination of two drugs (JS105 plus dalpiciclib and fulvestrant) against a standard combination (dalpiciclib plus fulvestrant) for people whose breast cancer has a PIK3CA mutation. The goal is to see if adding JS105 helps control the cancer longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07192614RecruitingPhase 1/Phase 2
Study of AZD6621 for men with advanced prostate cancer
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
Orlando, FloridaAges 18 years+ - NCT07136428RecruitingPhase 1/Phase 2
Asciminib for HER2+ breast cancer that has spread to the brain
This trial tests the drug asciminib for people with HER2-positive breast cancer that has spread to the brain and is growing. It may be an option if you have already tried standard treatments like T-DXd and tucatinib.
Durham, North CarolinaAges 18 years+ - NCT02971358Recruiting
Surgery for very high-risk or limited-spread prostate cancer
This trial looks at how safe and how well early prostate surgery works for men with newly diagnosed very high-risk prostate cancer or a limited number of metastases (cancer spread). It may help some people live longer and control the cancer, but eligibility is very specific.
ViennaAges 18–75 - NCT07003074RecruitingPhase 3
New drug TQB2102 vs standard therapy for HER2+ breast cancer
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
Hefei, AnhuiAges 18–75 - NCT06515470RecruitingPhase 1
Testing BTX-9341 for advanced breast cancer
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
Rochester, MinnesotaAges 18 years+ - NCT06962787RecruitingPhase 2
Study of BL-B01D1 + TKI with or without pembrolizumab for advanced kidney cancer
This trial is testing a new drug combination for people with advanced kidney cancer. The main drug, BL-B01D1, is given together with a targeted therapy (TKI) and sometimes also with an immunotherapy drug (pembrolizumab). The goal is to see if this combination can shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06954961RecruitingPhase 3
Study of D-0502 for ER+ HER2- advanced breast cancer
This trial tests an oral drug called D-0502 for people with a specific type of advanced breast cancer (ER-positive, HER2-negative). It is for those whose cancer has returned or worsened after hormone therapy, and it may be an option before trying more chemotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06755515Enrolling by invitationPhase 2/Phase 3
Rulonilimab + Chemo for Advanced Cervical Cancer
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
Linyi, ShandongAges 18 years+ - NCT06591650RecruitingPhase 2
Combination therapy for advanced gallbladder cancer
This trial is testing a combination of four drugs (gemcitabine, cisplatin, nab-paclitaxel, and durvalumab) for people with gallbladder cancer that has spread or cannot be removed by surgery. The goal is to see if this drug combination helps shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06253611RecruitingPhase 2
Probiotic plus immunotherapy and chemo for stomach cancer
This trial tests a new combination for advanced stomach cancer: an experimental probiotic (EXL01) plus standard immunotherapy (nivolumab) and chemotherapy (FOLFOX). It is for people whose tumors have a high PD-L1 marker and who have not received prior treatment for advanced disease.
AngersAges 18 years+ - NCT05850182Recruiting
Lifestyle program for metastatic prostate cancer on hormone therapy
This trial studies whether a structured lifestyle intervention (such as exercise and related behavior changes) can benefit people with metastatic prostate cancer who are currently on hormone treatment. It may help by improving health and functioning while you continue standard cancer therapy.
BellinzonaAges 18 years+ - NCT05950945RecruitingPhase 3
Trastuzumab deruxtecan for HER2-low metastatic breast cancer
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
Miami Beach, FloridaAges 18 years+ - NCT05095207RecruitingPhase 1/Phase 2
Abemaciclib and bicalutamide for HER2-negative metastatic breast cancer
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
New York, New YorkAges 18–90 - NCT05093231RecruitingPhase 2
Pembrolizumab plus olaparib for stage 4 pancreatic cancer
This trial tests whether combining pembrolizumab (an immunotherapy) with olaparib (a DNA-repair drug) can work better for people with metastatic (stage 4) pancreatic cancer. It targets tumors with certain lab marker results and aims to improve control of cancer growth.
MelbourneAges 18 years+ - NCT07538843Recruiting
Darolutamide Plus Hormone Therapy for Prostate Cancer in China
This study watches how well a drug called darolutamide works when combined with hormone therapy for men with prostate cancer that has returned after previous treatment. The goal is to understand if this combination helps prevent cancer spread and is safe to use.
Multiple LocationsAges 18 years+ - NCT07344311RecruitingPhase 1
CAR-T cell therapy for advanced prostate cancer
This trial tests a new immunotherapy called A-CAR032, which uses your own immune cells to attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06851299RecruitingPhase 2
Trop2-ADC alone or with immunotherapy for advanced triple-negative breast cancer
This study tests a new drug called Trop2-ADC, either alone or combined with immunotherapy, for people with advanced triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–70 - NCT05413850RecruitingPhase 1/Phase 2
Lu-177 PSMA drug study for advanced prostate cancer
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
Miami, FloridaAges 18 years+
Hear when a new Bone Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bone cancer metastatic?
- Yes. Clin2 currently lists 738 recruiting bone cancer metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bone cancer metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bone cancer metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.